Table 2.
Treatment characteristics
| Characteristic | All patients (n = 206) | Treatment group: n (%) |
P valuea | |
|---|---|---|---|---|
| TBI + chemotherapy (n = 90) | Chemotherapy alone (n = 116) | |||
| TBI-based regimen | ||||
| Cyclophosphamide | 32 (16) | 32 (36) | ||
| Melphalan | 13 (6) | 13 (14) | ||
| Etoposide | 2 (1) | 2 (2) | ||
| Fludarabine | 29 (14) | 29 (32) | ||
| Other/unavailable | 14 (7) | 14 (16) | ||
| Chemotherapy-alone regimen | ||||
| Busulfan/cyclophosphamide | 81 (39) | 81 (70) | ||
| Busulfan/fludarabine | 26 (13) | 26 (22) | ||
| Busulfan/melphalan | 9 (4) | 9 (8) | ||
| Transplant type | .004 | |||
| Matched related donor | 87 (42) | 27 (30) | 60 (52) | |
| Matched unrelated donor | 113 (55) | 59 (66) | 54 (47) | |
| Other/unavailable | 6 (3) | 4 (4) | 2 (2) | |
| Donor source | <.001 | |||
| Cord blood | 63 (31) | 48 (53) | 15 (13) | |
| Bone marrow | 1 (1) | 1 (1) | 0 (0) | |
| Peripheral blood | 137 (66) | 41 (46) | 96 (83) | |
| Unavailable | 5 (2) | 0 (0) | 5 (4) | |
| T-cell depletion | <.001 | |||
| Yes | 75 (36) | 18 (20) | 57 (49) | |
| Antithymocyte globulin | 25 (12) | 7 (8) | 18 (16) | |
| CD34 selection | 45 (22) | 9 (10) | 36 (31) | |
| Anti-CD52 antibody | 3 (1) | 0 (0) | 3 (3) | |
| Method unavailable | 2 (1) | 2 (2) | 0 (0) | |
| No | 125 (61) | 67 (74) | 58 (50) | |
| Unavailable | 6 (3) | 5 (6) | 1 (1) | |
| CMV baseline (donor) | .60 | |||
| Positive | 61 (30) | 26 (29) | 35 (30) | |
| Negative | 96 (47) | 45 (50) | 51 (44) | |
| Unknown | 49 (23) | 11 (21) | 30 (26) | |
| Successful engraftment | .18 | |||
| Yes | 179 (87) | 75 (83) | 104 (90) | |
| Nob | 27 (13) | 15 (17) | 12 (10) | |
| Days to engraftment | .26 | |||
| Median (IQR) | 30 (21-39) | 30 (23-42) | 30 (20-36) | |
| CMV reactivation | .09 | |||
| Yes | 76 (37) | 39 (43) | 37 (32) | |
| No | 130 (63) | 51 (57) | 84 (68) | |
| Acute GVHD | .09 | |||
| Grade 0-1 | 128 (62) | 50 (56) | 78 (67) | |
| Grade 2-4 | 78 (38) | 40 (44) | 38 (33) | |
GVHD, graft versus host disease. Other abbreviations as in Table 1.
a
Wilcoxon rank sum test for continuous variables and χ2 test for categorical variables.
b
Includes patients who died before engraftment.